CIDP Treatment & Adherence: Latest Strategies
- Pharmacists are essential in helping patients manage chronic inflammatory demyelinating neuropathy (CIDP) through education, logistical support, and proactive problem-solving, according to amy Duong, a clinical pharmacist at Yale...
- Effective management of CIDP relies heavily on patient understanding of their treatment.Duong emphasizes that early and continuous patient education is crucial.
- Beyond education, pharmacists play a significant role in logistical support.
Pharmacists are crucial for effective chronic inflammatory demyelinating neuropathy (CIDP) treatment.Learn how pharmacists help patients achieve medication adherence through education, logistical support, and proactive problem-solving. Discover how they assist with infusion scheduling and insurance hurdles to prevent treatment lapses. The latest advancements, like efgartigimod alfa, are transforming CIDP care, and pharmacists are key to implementing new therapies. News Directory 3 highlights the evolving role of pharmacists in CIDP management. Explore how they collaborate to ensure timely access and optimal outcomes. Discover what’s next …
Pharmacists Play Key Role in CIDP Medication Adherence
Updated June 14, 2025
Pharmacists are essential in helping patients manage chronic inflammatory demyelinating neuropathy (CIDP) through education, logistical support, and proactive problem-solving, according to amy Duong, a clinical pharmacist at Yale New haven Health. Duong highlighted the importance of pharmacists in ensuring medication adherence and staying informed about new therapies for CIDP.
Effective management of CIDP relies heavily on patient understanding of their treatment.Duong emphasizes that early and continuous patient education is crucial. This includes explaining how therapies work, what improvements to expect, and potential side effects.For patients on steroid tapers, pharmacists review schedules to ensure proper dosage reduction and discuss the risks of abrupt discontinuation. They may also recommend therapies for bone protection or gastrointestinal issues, depending on the steroid dosage and duration.
Beyond education, pharmacists play a significant role in logistical support. Duong assists patients with coordinating infusion scheduling and investigates any scheduling issues. This involves troubleshooting transportation problems or insurance delays to prevent treatment lapses. Pharmacists also help with insurance reauthorization to ensure continuous coverage for patients’ treatment plans. This extensive approach to CIDP management ensures patients receive the support they need to adhere to their medication regimens.
The treatment landscape for CIDP is evolving, and pharmacists must stay informed about emerging therapies. Duong noted the approval of efgartigimod alfa and hyaluronidase-qvfc in July 2024, which offers a new mechanism of action. In April 2025, a prefilled syringe formulation was approved, allowing patients to self-administer the medication weekly without needing a healthcare professional. This advancement reduces the burden of scheduled infusion appointments. Research continues on anti-CD20 antibodies, FcRn receptor antagonists, and complement inhibitors, offering hope for future treatment options.
To stay updated, Duong encourages pharmacists to attend professional meetings and consult trusted resources like the GBS/CIDP Foundation. When new therapies are introduced, she collaborates with her clinical-end pharmacy team to identify suitable patients, educate staff and patients, and assist with operational steps. This includes integrating new treatments into electronic medical records and navigating prior authorizations to ensure timely access for patients.
What’s next
As research progresses,pharmacists will continue to play a vital role in implementing new CIDP therapies and ensuring optimal patient outcomes through comprehensive medication management.